Is Cancer Incidence Modified by SGLT2 Inhibitors?

Diabetes Mellitus - Russian Federation
doi 10.14341/dm10119
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Endocrinology Research Centre

Related search

SGLT2 Inhibitors

2020English

SGLT2 Inhibitors: Mind the Gap

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2016English

SGLT2 Inhibitors: Alternatives or Complementary Therapeutic Options

2020English

Class Effects of SGLT2 Inhibitors on Cardiorenal Outcomes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2019English

Is the Renoprotective Effect of SGLT2 Inhibitors Due to Their Beneficial Effect on Hypomagnesemia?

Journal of Diabetes & Metabolism
2017English

Sarcopenia, Frailty Circle, and Treatment With SGLT2 Inhibitors

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2018English

SGLT2 Inhibitors for Primary Prevention of Cardiovascular Events

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Diabetes Research Open Access: Sodium Glucose Cotransporter2 (SGLT2) Inhibitors

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy